

The Epidemiological Effect of RSV on the Community

Type: Review Article

Received: October 23, 2023

Published: November 15, 2023

Citation:

Nemat Khansari. "The Epidemiological Effect of RSV on the Community". PriMera Scientific Surgical Research and Practice 2.6 (2023): 09-16.

Copyright:

© 2023 Nemat Khansari. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nemat Khansari*

Tehran University of Medical Sciences, School of Medicine, Department of Immunology

***Corresponding Author:** Nemat Khansari, Tehran University of Medical Sciences, School of Medicine, Department of Immunology.

Abstract

Respiratory viral infections are caused by a diverse group of viruses, including influenza A and B viruses, severe acute respiratory syndrome virus 2, respiratory syncytial virus, and human rhinovirus. Respiratory syncytial virus (RSV) is a common and highly contagious virus that affects the lower respiratory tract and can lead to severe illness in infants, young children, and older adults. After more than 60 years of research for developing an efficient vaccine against this single-stranded virus, the Center for Disease Control and Prevention (CDC) recently recommended two newly developed RSV vaccines, RSVPreF3OA (Arexvy) by GlaxoSmithKline (GSK) and RSVpreF (Abrysvo) by Pfizer. Both vaccines are approved to be administered as a single dose for ages 60 and older but Abrysvo is for those between 32 to 36 weeks of pregnancy to help protect their newborns. According to a CDC report, there are no substantial differences between these two vaccines and both were 80 to 90 percent effective in reducing RSV illness during the first season after vaccination. This article will discuss the epidemiological effects of RSV in the community, focusing on its prevalence, transmission, diagnostics, treatment, and prevention strategies.

Keywords: RSV; Vaccine; Infection; Immunity; Prevention

Prevalence of RSV

The RSV was first discovered in 1952 as the cause of a serious lower respiratory tract disease, most pronounced among children in their first year of life [1]. This is a single-stranded RNA virus in the family Paramyxoviridae, the subfamily Pneumovirinae and the genus Pneumovirus whose genome includes 10 genes encoding 11 proteins. Two surface proteins, the F (fusion) protein and the G (attachment glycoprotein) protein, are the major viral antigens and play a critical role in the virulence of RSV. The G protein mediates RSV attachment to the host cell, after which the F protein enables the fusion of the host and viral plasma membranes to permit virus passage into the host cell. The F protein also promotes the aggregation of multinucleated cells through the fusion of their plasma membranes, producing the syncytia for which the virus is named and allowing the transmission of the virus from cell to cell. RSV has 2 distinct antigenic sub-types, A and B, which are usually present in the communities during seasonal outbreaks [2].

RSV is the most common cause of severe bronchiolitis and pneumonia in children under one year of age. Other individuals who are susceptible to severe RSV disease include patients with cardiac and pulmonary disorders, patients with immunodeficiencies, and the elderly [3]. RSV infection generally first, presents as an upper respiratory tract infection which progresses for several days before the virus traffics to the lung and affects the lower respiratory tract [4]. Most infants are able to clear the virus without extreme adverse events, but in the United States, approximately 2% require hospitalization [5]. Globally, RSV infections are estimated to result in more than 200,000 deaths annually in children under 5 years of age [6], while treatment options remain controversial. It is estimated that nearly all children will have been infected with RSV by the time they turn two years old [7]. In the United States, RSV infections typically occur during the fall, winter, and spring months, with a peak in January and February. According to a CDC report, up to 80,000 children younger than 5 are hospitalized yearly for RSV, and as many as 300 die. Between 60,000 and 160,000 people aged 65 or older are hospitalized yearly for RSV with 6,000 to 10,000 fatalities [8]. RSV has been shown to play a significant role in exacerbating asthma and other chronic respiratory conditions. In individuals with pre-existing respiratory issues, an RSV infection can lead to increased inflammation, worsened symptoms, and even hospitalization. Studies have demonstrated that RSV infections can trigger asthma exacerbations in both children and adults [9]. In some cases, severe RSV infections during infancy have been linked to the development of childhood asthma. Furthermore, individuals with asthma are more likely to experience complications from an RSV infection, such as severe bronchitis or pneumonia. While the connection between RSV infections and asthma is relatively well-established, the relationship between RSV and other atopic diseases such as eczema or allergic rhinitis remains less clear. Some studies have reported associations between early-life RSV infections and an increased prevalence of these conditions, but further research is needed to confirm these findings and elucidate potential underlying mechanisms [10]. There is evidence suggesting that severe RSV infections in early childhood may contribute to the development of allergies or atopic diseases later in life. A better understanding of this relationship could inform strategies for preventing or mitigating the long-term health consequences associated with RSV infection. Chronic obstructive pulmonary disease (COPD) is another long-term lung condition that can be worsened by an RSV infection. COPD encompasses conditions like emphysema and chronic bronchitis, which are characterized by airflow obstruction and damage to the lungs' air sacs. Individuals with COPD who contract RSV may experience a worsening of their symptoms, such as increased shortness of breath, coughing, and mucus production. Additionally, an RSV infection can increase the risk of acute exacerbations in COPD patients, leading to hospitalization or even death [11].

Transmission of RSV

RSV is highly contagious and can be spread through direct contact, respiratory droplets, and contaminated surfaces. The virus can survive on surfaces for several hours, increasing the risk of transmission. Common ways RSV spreads in the community include [12]:

- Close contact with an infected person, such as hugging or shaking hands.
- Touching contaminated surfaces and then touching the eyes, nose, or mouth.
- Breathing in respiratory droplets from an infected person's cough or sneeze.

Climate, Geography, and Seasonality in RSV Transmission Patterns

- The transmission patterns of RSV are influenced by a combination of factors, including climate, geography, and seasonality. Understanding the role that climate, geography, and seasonality play in RSV transmission patterns can help public health officials develop targeted interventions aimed at reducing infection risk during peak seasons. This might include promoting hand hygiene practices, implementing infection control measures in schools or long-term care facilities, or allocating resources towards healthcare services that anticipate an increase in demand related to RSV infections.
- **Climate:** Climatic conditions such as temperature and humidity can impact the survival and spread of RSV. Generally, cooler temperatures and lower humidity levels create an environment more conducive to the transmission of respiratory viruses like RSV. This is because the virus particles can remain viable for longer periods on surfaces or in aerosols under these conditions.
- **Geography:** Geographical location plays a significant role in determining the timing and intensity of RSV outbreaks. In temperate regions, RSV infections typically peak during winter months when temperatures are low and people spend more time indoors

with close contact. In contrast, tropical regions may experience year-round circulation of RSV with seasonal peaks that coincide with rainy seasons or other climatic changes.

Seasonality: Seasonal variations in weather patterns contribute to fluctuations in RSV infection rates throughout the year. As mentioned earlier, colder climates tend to see increased rates of transmission during winter months when people are indoors more frequently due to unfavorable outdoor conditions. Additionally, children returning to school or daycare settings in the fall may facilitate increased transmission among susceptible populations due to close contact.

Demographic Factors Influencing RSV Infection Rates: Certain demographic factors, such as age and socioeconomic status, play a significant role in the susceptibility to and severity of RSV infections. Understanding these factors can help inform targeted prevention efforts and resource allocation. Risk for severe RSV infections due to age-related declines in immune function, pre-existing health conditions, or living in long-term care facilities. Socioeconomic status (SES) has been shown to impact RSV infection rates and outcomes. Lower SES is often associated with factors that can increase the risk of RSV transmission or exacerbate the severity of infections [13]:

- **Age:** Age is a critical factor that influences RSV infection rates. Infants and young children under two years old are particularly vulnerable due to their immature immune systems and developing respiratory tracts. Older adults, especially those above 65 years of age, are also at an increased
- **Crowded living conditions:** Families with lower incomes may live in smaller homes or apartments with limited space, leading to close contact among household members and higher chances of virus transmission.
- **Limited access to healthcare:** Individuals from lower-income backgrounds may have less access to healthcare services or face financial barriers that prevent them from seeking timely medical care for themselves or their children.
- **Environmental factors:** Exposure to air pollution, tobacco smoke, or allergens may be more common in lower SES households or neighborhoods, which can contribute to compromised respiratory health and increased vulnerability to RSV infections.
- **Nutritional deficiencies:** Poor nutrition resulting from food insecurity can weaken the immune system's ability to fight off infections like RSV.

By recognizing the demographic factors that influence RSV infection rates, public health officials and healthcare providers can develop targeted interventions aimed at reducing disparities in infection risk and improving outcomes for vulnerable populations. Such strategies might include outreach programs promoting vaccination, education on preventative measures tailored for specific age groups, or increased access to healthcare services in underprivileged communities. Public health campaigns and education programs play a crucial role in reducing the transmission of Respiratory Syncytial Virus (RSV) within communities. These initiatives aim to raise awareness about RSV prevention, risk factors, and appropriate management strategies.

Awareness and Prevention Measures: Effective public health campaigns can increase awareness about RSV transmission routes, such as direct contact with respiratory secretions or contaminated surfaces. By educating the general public on preventive measures, these initiatives contribute to reduced infection rates. Key prevention strategies include:

- **Hand hygiene:** Emphasizing the importance of regular hand-washing to minimize the spread of RSV.
- **Respiratory etiquette:** Encouraging individuals to cover their mouth and nose while coughing or sneezing, minimizing the release of infectious particles.
- **Environmental cleaning:** Promoting regular disinfection of frequently touched surfaces to reduce contamination risks.

Identifying High-Risk Populations: Education programs targeting healthcare providers can help identify individuals at higher risk for severe RSV infections, such as premature infants, older adults, or those with underlying respiratory conditions. Timely identification enables healthcare professionals to implement appropriate interventions like palivizumab prophylaxis or prioritize these individuals during potential future vaccination campaigns.

Early Recognition and Management: Educational efforts aimed at parents, caregivers, and educators can empower them to recognize early signs of RSV infection in children. Prompt recognition allows for timely medical intervention that may prevent complications or hospitalizations. Additionally, understanding when self-isolation is necessary can help control disease spread within households or schools.

Community-Based Interventions: Collaborative public health initiatives involving community stakeholders like schools, daycare centers, nursing homes, and local governments can create a supportive environment for implementing effective prevention measures. These partnerships facilitate resource sharing for educational materials, access to healthcare services, and the promotion of best practices in mitigating RSV transmission.

Diagnostic Methods for Detecting RSV Infections and Their Limitations

Accurate and timely diagnosis of RSV infections is crucial for patient management and infection control measures. Current, diagnostic methods are available for detecting RSV infections and their limitations are [14]:

Rapid Antigen Detection Tests (RADTs): Rapid antigen detection tests (RADTs) are point-of-care tests that detect the presence of viral antigens in respiratory specimens, such as nasal swabs or washes. These tests can provide results within minutes, making them useful in clinical settings where a quick diagnosis is needed. However, RADTs have several limitations:

- **Sensitivity:** RADTs may have lower sensitivity compared to other diagnostic methods, leading to false-negative results, especially in cases with low viral loads.
- **Specificity:** While RADTs are generally specific for RSV, there is a risk of cross-reactivity with other respiratory viruses, which could result in false-positive results.

Viral Culture: Viral culture involves isolating the virus from respiratory specimens and growing it in a laboratory setting. This method can provide definitive evidence of an active RSV infection but has some drawbacks:

- **Time-consuming:** Viral culture can take several days to produce results, making it less suitable for situations requiring immediate intervention or treatment.
- **Labor-intensive:** This method requires specialized laboratory facilities and skilled personnel to perform the test accurately.

Polymerase Chain Reaction (PCR) Testing: PCR testing is a highly sensitive molecular technique that detects the presence of viral RNA or DNA in respiratory specimens. Reverse transcription PCR (RT-PCR) is commonly used for diagnosing RSV infections due to its high sensitivity and specificity. However, PCR testing also has some limitations:

- **Cost:** PCR tests tend to be more expensive than other diagnostic methods, making them less accessible in resource-limited settings.
- **Turnaround time:** Although faster than viral culture, PCR tests still require several hours to generate results, which may not be ideal for rapid decision-making in clinical settings.

Serological Testing: Serological testing measures the presence of specific antibodies against RSV in a patient's blood. This method can help determine if an individual has been exposed to the virus but has some notable limitations:

- **Timing:** Since it takes time for the immune system to produce detectable levels of antibodies, serological testing is less useful for diagnosing acute infections.
- **Cross-reactivity:** There is a risk of cross-reactivity with antibodies produced in response to other respiratory viruses, which could lead to false-positive results.

While various diagnostic methods are available for detecting RSV infections, each comes with its own set of limitations. Accurate and timely diagnosis remains crucial for patient management and implementing appropriate infection control measures. Advancements in

diagnostic technology and the development of more cost-effective and rapid testing methods could significantly improve RSV detection and overall patient care.

Antiviral Medications for Severe RSV Infections and Their Effectiveness

Antiviral medications can be used to treat severe cases of RSV infection, particularly in high-risk individuals such as infants, older adults, or those with underlying respiratory conditions. Following are most of the available antiviral medications for RSV infections:

Ribavirin: Ribavirin is a broad-spectrum antiviral drug that has been used to treat severe RSV infections, especially in high-risk patients. It is administered either orally, intravenously, or in an aerosolized form for inhalation therapy. The effectiveness of ribavirin in treating severe RSV infections has been debated due to varying results from clinical studies [15]:

- **Benefits:** Some studies have shown that ribavirin treatment can shorten the duration of hospitalization and reduce the need for mechanical ventilation in severe RSV cases.
- **Limitations:** Other research has reported limited or no significant improvement in clinical outcomes after ribavirin treatment. Additionally, ribavirin is associated with potential side effects such as hemolytic anemia and teratogenicity.

Due to these mixed results and potential risks, the use of ribavirin for treating RSV infections remains controversial and is generally reserved for severe cases where other treatments have failed.

Palivizumab: Palivizumab is a monoclonal antibody specifically designed to target the fusion protein of RSV. While it is not an antiviral medication per se, it is used as a prophylactic measure to prevent serious complications from RSV infection in high-risk infants. Palivizumab is administered through monthly intramuscular injections during the peak RSV season [16].

- **Effectiveness:** Studies have demonstrated that palivizumab can significantly reduce the incidence of hospitalization due to severe RSV infection in high-risk infants, such as those born prematurely or with chronic lung disease.
- **Limitations:** Palivizumab is not effective in treating active RSV infections and is solely used for prevention. Furthermore, its high cost may limit accessibility for some patients.

Future Antiviral Medications: There are several antiviral medications currently under development for the treatment of RSV infections. These new drugs aim to target various stages of the viral replication process and offer potential alternatives to existing treatment options. Some promising candidates include:

- **Fusion inhibitors:** These drugs work by inhibiting the fusion of RSV with host cells, preventing viral entry and replication. Examples include presatovir and AK0529, which are currently undergoing clinical trials.
- **Replication inhibitors:** Compounds targeting the RNA-dependent RNA polymerase (RdRp) of RSV can inhibit viral replication. One example is ALS-008176 (lumicitabine), which has shown promising results in early-stage clinical trials [17].

It should be noted that there are limited antiviral medications available for treating severe RSV infections, ongoing research holds promise for the development of more effective and targeted therapies. Until then, ribavirin remains an option for severe cases where other treatments have failed, and palivizumab serves as a preventative measure in high-risk infants.

Prevention Strategies

Currently, there are only two vaccines available for preventive measures (Arexvy and Abrysvo). These two vaccines just have been approved for elderly and pregnant people [18-20] but there is not enough data to support their long-term immunity and even herd immunity; thus, prevention relies on good hygiene practices and other preventative measures. To reduce the risk of RSV transmission in the community, the following strategies are recommended:

1. **Hand hygiene:** Wash hands frequently with soap and water for at least 20 seconds, especially after contact with an infected person or touching surfaces in public areas.

2. **Avoid close contact:** Stay away from people who are sick or have respiratory symptoms, and avoid close contact with infants and young children if you have cold-like symptoms.
3. **Cover coughs and sneezes:** Use a tissue or your elbow to cover your mouth and nose when coughing or sneezing, and dispose of tissues in a lined trash can.
4. **Clean and disinfect surfaces:** Regularly clean and disinfect frequently touched surfaces in your home, such as doorknobs, light switches, and countertops.
5. **Stay home when sick:** If you're experiencing cold-like symptoms, stay home from work or school to prevent spreading the virus to others.

Given the potential complications associated with RSV infections in those with asthma or COPD, it is crucial for these high-risk individuals to take extra precautions during the RSV season. In addition to following the general prevention strategies mentioned earlier:

- **Consult healthcare providers:** High-risk individuals should regularly consult their healthcare providers about managing their respiratory conditions and any additional measures they can take to reduce their risk of contracting RSV.
- **Monitor symptoms:** Pay close attention to any changes in respiratory symptoms and seek medical attention promptly if they worsen or if signs of an RSV infection are present.
- **Consider prophylactic treatment:** In some cases, healthcare providers may recommend the use of prophylactic medications, such as palivizumab, to help prevent severe RSV infections in high-risk infants.

The Concept of Herd Immunity in Respiratory Viruses: Herd immunity refers to the phenomenon of indirect protection from infectious diseases when a significant proportion of a population is immune, either through vaccination or previous infection. This section will examine the role of herd immunity in RSV transmission and its potential impact on infection rates. For respiratory viruses such as RSV, achieving herd immunity can be challenging due to several factors:

- **Waning immunity:** The immune response to RSV tends to be short-lived, meaning individuals may become susceptible to reinfection within a few years. This makes it difficult to maintain a high level of population immunity over time.
- **Variability in viral strains:** RSV has two main subtypes (A and B) that can further divide into multiple genotypes. Although cross-protection between subtypes exists, the variability among circulating strains may affect the overall efficacy of herd immunity.
- **Age-specific susceptibility:** Different age groups have varying levels of susceptibility to RSV infection. Infants are particularly vulnerable due to their immature immune systems, while older adults might experience waning immunity with age.

Despite these challenges, achieving some degree of herd immunity could potentially reduce RSV transmission and infection rates:

- **Reduced disease burden:** With higher levels of population immunity, there would be fewer susceptible individuals for the virus to infect. This could lead to decreased transmission rates and reduced overall disease burden.
- **Protection for vulnerable populations:** Achieving herd immunity could indirectly protect those who are most at risk for severe RSV infections, such as infants and older adults with weakened immune systems or underlying health conditions.

Decreased healthcare utilization: Reduced infection rates due to herd immunity could result in lower hospitalization rates and decreased strain on healthcare resources.

In conclusion, although achieving herd immunity for RSV poses unique challenges, its potential impact on infection rates and vulnerable populations could be significant. The development of an effective vaccine that provides long-lasting immunity may play a crucial role in harnessing the power of herd immunity against RSV transmission.

Impact of RSV on Healthcare Costs and Resource Utilization

RSV infections not only pose significant health risks to vulnerable populations but also lead to substantial healthcare costs and

resource utilization. The burden of RSV on healthcare systems can be attributed to hospitalizations, outpatient visits, emergency department visits, and long-term care facility admissions. The direct medical costs associated with RSV infections include expenses related to hospitalizations, medications, diagnostic tests, and physician consultations. In the United States, it is estimated that annual RSV-related healthcare costs amount to over \$1 billion for infants and young children alone. For older adults aged 65 years and above, the annual cost is estimated to be around \$2 billion. Indirect costs related to RSV infections involve productivity losses due to missed work or school days for patients or caregivers. Additionally, this category includes expenses incurred from the long-term consequences of severe RSV infections in early childhood, such as developmental delays or chronic respiratory conditions requiring ongoing medical care. The high prevalence of RSV infections during peak seasons places a significant strain on healthcare resources. Hospitals may experience increased occupancy rates due to RSV-related admissions, leading to limited bed availability for other patients. Emergency departments often face overcrowding during peak seasons as well, with many individuals seeking urgent care for respiratory symptoms caused by RSV infections. Moreover, healthcare providers may need to allocate additional staff and resources toward managing outbreaks in long-term care facilities where older adults are at higher risk of developing severe complications from RSV infections [21].

Strategies for Reducing Healthcare Burden: To alleviate the financial and resource burden of RSV on healthcare systems, several strategies can be employed:

- **Promote prevention:** By encouraging good hygiene practices and implementing infection control measures in public spaces and long-term care facilities, the transmission of RSV can be reduced.
- **Invest in research and development:** Continued efforts to develop an effective RSV vaccine or antiviral treatment can potentially decrease the incidence of severe infections, hospitalizations, and associated healthcare costs.
- **Educate caregivers and high-risk individuals:** Raising awareness about the risks of RSV among caregivers of young children and individuals with chronic respiratory conditions may help them take appropriate precautions to minimize exposure during peak seasons.

Conclusion

RSV is a significant cause of respiratory illness in infants, young children, and older adults. Understanding its prevalence, transmission, and prevention strategies can help to reduce its epidemiological impact on the community and protect vulnerable populations. By understanding the link between RSV and chronic respiratory conditions like asthma and COPD, individuals at higher risk can take appropriate precautions to minimize their chances of experiencing complications from an RSV infection. Developing an effective vaccine for Respiratory Syncytial Virus (RSV) has been a priority in the field of infectious diseases research for decades. A safe and efficient vaccine could significantly reduce the burden of RSV infections on healthcare systems and vulnerable populations, such as infants and older adults. Furthermore, by addressing the impact of RSV on healthcare costs and resource utilization, healthcare systems can better manage the challenges posed by this highly contagious virus while providing optimal care for affected patients. While significant progress has been made in RSV vaccine research, several challenges remain:

- **Immune Response Complexity:** The immune response to RSV is complex and not yet fully understood. Developing a vaccine that can safely induce protective immunity without causing harmful side effects remains a major challenge.
- **Target Population Considerations:** Different populations, such as infants, older adults, and pregnant women, may require tailored vaccination strategies due to differences in immune system maturity or pre-existing health conditions.
- **Efficacy Duration:** Ensuring long-lasting protection against RSV through vaccination is crucial for reducing infection rates and healthcare burden.

References

1. Groothuis JR, Gutierrez KM and Lauer BA. "Respiratory syncytial virus infection in children with bronchopulmonary dysplasia". *Pediatrics* 82 (1988): 199-203.

2. Piedimonte G and Perez MK. "Respiratory Syncytial virus infection and bronchiolitis". *Virology* 35 (2014): 519-529.
3. Madhi SA., et al. "Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1". *J. Pediatr* 137 (2000): 78-84.
4. Wright PF, et al. "Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus". *J. Infect. Dis* 185 (2002): 1011-1018.
5. Thompson WW., et al. "Mortality associated with influenza and respiratory syncytial virus in the United States". *JAMA* 289 (2003): 179-186.
6. Nair, H., et al. "Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis". *Lancet* 375 (2010): 1545-1555.
7. Rudraraju R., et al. "Respiratory syncytial virus: current progress in vaccine development". *Viruses* 5 (2013): 577-594.
8. CDC Reports on RSV vaccination recommendations (2023).
9. Kuehni CE, Spycher BD and Silverman M. "Causal links between RSV infection and asthma: no clear answers to an old question". *Am J Respir Crit Care Med* 179 (2009): 1079-80.
10. Holt PG and Sly PD. "Interactions between RSV infection, asthma, and atopy: unraveling the complexities". *J. Exp. Med* 196 (2002): 1271-1275.
11. Pratt MTG., et al. "Prevalence of respiratory viruses in community-acquired pneumonia in children: a systematic review and meta-analysis". *Lancet Child Adolesc. Health* 6 (2022): 555-570.
12. Otomaru H., et al. "Risk of Transmission and Viral Shedding from the Time of Infection for Respiratory Syncytial Virus in Households". *Am J Epidemiol* 190 (2021): 2536-2543.
13. Moore HC., et al. "Modeling the seasonal epidemics of respiratory syncytial virus in young children". *PLoS One* 9 (2014): e100422.
14. Xu YZ., et al. "Utilization of recombinase polymerase amplification method combined with lateral flow dipstick for visual detection of respiratory syncytial virus". *Mol. Cell Probes* 49 (2020): 1014-1023.
15. Mooney K, Melvin M and Douglas T. "Ribavirin: the need for exposure precautions". *Clin. J. Oncol. Nurs* 18 (2014): E93-96.
16. Garegnani L., et al. "Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children". *Cochrane Database Syst. Rev* 11 (2021): 1375-1380.
17. Patel K., et al. "Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans". *J. Antimicrob. Chemother* 74 (2019): 442-452.
18. Kampmann B., et al. "Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants". *N. Engl. J. Med* 388 (2023): 1451-1464.
19. Walsh EE., et al. "Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults". *N. Engl. J. Med* 388 (2023): 1465-1477.
20. Papi A., et al. "Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults". *N. Engl. J. Med* 388 (2023): 595-608.
21. Paramore LC., et al. "Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases". *Pharmaco Economics* 22 (2004): 275-284.